FLOCK Cluster Analysis of Mast Cell Event Clustering by High-Sensitivity Flow Cytometry Predicts Systemic Mastocytosis

Size: px
Start display at page:

Download "FLOCK Cluster Analysis of Mast Cell Event Clustering by High-Sensitivity Flow Cytometry Predicts Systemic Mastocytosis"

Transcription

1 FLOCK Cluster Analysis of Mast Cell Event Clustering by High-Sensitivity Flow Cytometry Predicts Systemic Mastocytosis David M. Dorfman, MD, PhD, Charlotte D. LaPlante, Olga Pozdnyakova, MD, PhD, and Betty Li, MS, MT(ASCP) From the Department of Pathology, Brigham and Women s Hospital and Harvard Medical School, Boston, MA. Key Words: Systemic mastocytosis; Flow cytometry; Cluster analysis Am J Clin Pathol November ;:- ABSTRACT Objectives: In our high-sensitivity flow cytometric approach for systemic mastocytosis (SM), we identified mast cell event clustering as a new diagnostic criterion for the disease. Methods: To objectively characterize mast cell gated event distributions, we performed cluster analysis using FLOCK, a computational approach to identify cell subsets in multidimensional flow cytometry data in an unbiased, automated fashion. Results: FLOCK identified discrete mast cell populations in most cases of SM (/ [%]) but only a minority of non-sm cases (/ [%]). FLOCK-identified mast cell populations accounted for.% of total cells on average in SM cases and.% of total cells on average in non-sm cases (P <.) and were predictive of SM, with a sensitivity of %, a specificity of %, a positive predictive value of %, and a negative predictive value of %. Conclusions: FLOCK analysis provides useful diagnostic information for evaluating patients with suspected SM, and may be useful for the analysis of other hematopoietic neoplasms. Systemic mastocytosis (SM) is a neoplasm of mast cells in which they proliferate in bone marrow and other organs. Based on World Health Organization (WHO) diagnostic criteria, the diagnosis of SM requires the presence of mast cell infiltrates in bone marrow or other extracutaneous organs (the major diagnostic criterion) and/or a number of minor diagnostic criteria, which include atypical mast cell morphology, the DV KIT mutation, elevated serum tryptase, and aberrant CD and/or CD antigen expression. However, the major diagnostic criterion is not seen in % to % of indolent SM cases, and strict use of the current WHO criteria results in false-negative SM cases, especially in early disease stages with low disease burden., Recently, we described a high-sensitivity flow cytometric approach for evaluation of patients with SM that identified the presence of discrete mast cell event clustering as a new diagnostic criterion for the disease. All cases that exhibited event clustering within the mast cell gate were found to have fulfilled WHO diagnostic criteria for SM, whether or not the mast cells exhibited aberrant CD and/or CD expression. Utilization of this mast cell event clustering criterion, along with the presence of aberrant expression of CD and/or CD, increased the diagnostic sensitivity of flow cytometric analysis for the diagnosis of SM to %, which exceeds the diagnostic sensitivity of bone marrow biopsy examination (%) or the bone marrow aspirate examination (%). Our subsequent statistical analysis found that cells within a broadly defined /side-scatter characteristic () mast cell gate had significantly lower coefficients of variation (CVs) for mean fluorescent intensity and in cases of SM compared with non-sm cases. Flow Am J Clin Pathol ;:-

2 A Dimension B Dimension C Dimension D Dimension Figure FLOCK analysis involves (A) partitioning of flow cytometry data based on multiple measured characteristics, such as fluorescence due to antibody binding or side scatter of light into equal-sized bins; (B) identification of data-dense regions that exceed a minimum density threshold (shown in red); (C) merging of neighboring data-dense regions into clusters, which are each assigned a unique color; and (D) final clustering of events by assignment to the nearest cluster. Each cluster has a centroid, which is the point whose coordinates are the averages of the corresponding coordinates of all the points within the cluster. FLOCK calculates the percentage of the total population present in each identified cluster. Reproduced with permission from Qian et al. cytometrically identified mast cell event clustering was associated with significantly lower CVs for and than cases without mast cell event clustering. A combined CV ( + ) of or less showed a sensitivity of % and a specificity of % for SM with a positive predictive value (PPV) of % and a negative predictive value (NPV) of %. Probability scores of having SM, based on CVs for and, were significantly higher in patients with SM than in those without SM (. vs., respectively; P <.). In our prior studies, flow cytometric and statistical analyses were based on manual gating of mast cell populations using a uniform, broadly defined mast cell gate, but not all SM cases showed mast cell event clustering or a consistent distribution of mast cells within the mast cell gate., To objectively characterize event distributions within the mast cell gate and identify discrete mast cell populations, we performed cluster analysis using FLOCK, a computational approach that uses algorithms and density-based clustering to identify cell subsets in multidimensional flow cytometry data in an unbiased, automated fashion, eliminating operator-dependent variability Figure. FLOCK has been employed to objectively identify B-cell and T-cell subsets, based on flow cytometric data, in patients following vaccination for tetanus, typhoid, and influenza vaccination; in toxic shock syndrome; and during acute and chronic virus infection. - To our knowledge, FLOCK has not until now been used to objectively identify neoplastic cell populations from multiparametric flow cytometric analysis. In this study, we investigated whether FLOCK could identify discrete mast cell populations based on flow cytometric data and whether the presence of FLOCK-identified mast cell populations is associated with SM. Materials and Methods Cases and Prior High-Sensitivity Flow Cytometric Analysis The Brigham and Women s Hospital hematology laboratory previously performed flow cytometric analysis on consecutive bone marrow aspirate samples from patients being evaluated for SM. Seventy-five samples came from Am J Clin Pathol ;:-

3 Dorfman et al / FLOCK Analysis in Systemic Mastocytosis patients who fulfilled the diagnostic criteria for SM after complete evaluation, and samples came from patients without SM who had various diagnoses, including nonclonal mast cell disorders, low-grade B-cell lymphoproliferative disorders, myeloid malignancies, and autoimmune disorders. Flow cytometric results from the bone marrow aspirates were previously correlated with the results of the concurrent bone marrow biopsy specimen, as well as molecular diagnostic, other laboratory, and clinical findings. The diagnosis of SM was based on the WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Clinical information was collected through chart review. High-sensitivity flow cytometric analysis of mast cells was previously performed on a Becton Dickinson (Franklin Lakes, NJ) FACSCanto flow cytometer using the following antibodies: -PE, CD- APC, and CD-FITC with respective fluorochrome isotype controls from BD Biosciences (San Jose, CA). The number of collected events per sample ranged from, to,, (mean,, events; median,, events), and in most samples, the number of collected events was, or more. A broad, uniform mast cell gate was employed for all cases and included all -bright events (x-axis between and on the logarithmic scale) and all events on the y-axis (side scatter characteristic [], linear axis; Figure ) regardless of the presence or absence of cluster formation. The number of events within the mast cell gate ranged from to, and followed two distribution patterns: cases showed mast cell event clustering, and cases displayed scattered events within the mast cell gate. Studies were performed with the institutional review board s permission. FLOCK Analysis FLOCK analysis was performed using flow cytometry standard format file data from the specimens evaluated by flow cytometric analysis for SM (see above). FLOCK is available at the Immunology Database and Analysis Portal ( FLOCK analysis was employed to investigate / flow cytometry data, determine the number of FLOCK-identified cell populations present, determine if a discrete population was identified in the / mast cell gated area, and, if so, determine the size of the mast cell population identified by FLOCK. Cell populations that were uniformly distributed throughout the broadly defined / mast cell gate or that were included as part of other FLOCK-identified populations outside of the mast cell gated area were not regarded as discrete mast cell populations. In a small subset of SM cases, FLOCK identified a uniform, discrete population within the mast cell gated area and overpartitioned it into more than one population (data not shown). In such cases, mast cell population size comprises the sum of the sizes of the uniform, discrete but partitioned total mast cell population. Statistical Analysis Statistical analysis was performed using GraphPad Prism version. (GraphPad Software, La Jolla, CA). Results FLOCK Analysis Seventy-five specimens from patients who fulfilled WHO diagnostic criteria for SM and cases from patients negative for mastocytosis after diagnostic workup (non-sm) were evaluated by FLOCK analysis and compared with prior flow cytometric analysis. There was no significant difference in the number of cell populations identified by FLOCK from the / flow cytometry data in SM cases (. ±. populations) and non-sm cases (. ±. populations; P =., Mann-Whitney). Representative FLOCK results for SM and non-sm cases are shown in Figure. In cases ( SM and non-sm cases), FLOCK identified discrete populations within the flow cytometric / mast cell gate, while cases ( SM and non-sm cases) showed no discrete populations in the / mast cell gate. All SM cases that showed flow cytometry based event clusters exhibited discrete mast cell populations by FLOCK analysis (Figure ). These discrete mast cell populations ranged in size from.% to.% of total cells (mean,.%) and correlated with flow cytometry based total / mast cell gated events (R =.) Figure. FLOCK identified discrete mast cell populations in eight (%) of SM cases without apparent flow cytometry based event clusters Figure A, which ranged in size from.% to.% of total cells (mean,.%). Combining all FLOCK-positive SM cases, FLOCK-identified mast cell populations ranged in size from.% to.% of total cells (mean,.%). FLOCK identified discrete mast cell populations in two of two non-sm cases with flow cytometry based event clusters, which accounted for.% and.% of total cells Figure B. In addition, FLOCK identified discrete mast cell populations in (%) of non-sm cases without apparent flow cytometry based event clusters Figure C, ranging in size from.% to.% of total cells (mean,.%). Combining all non-sm cases with FLOCK-identified discrete mast cell populations, the populations ranged in size from.% to.% of total cells (mean,.%). There was a statistically significant difference in FLOCKidentified mast cell population sizes in SM cases compared with non-sm cases (P <., Mann-Whitney) Figure. Receiver operating characteristic (ROC) curve analysis of FLOCK-based mast cell population size as a diagnostic criterion for SM was performed based on discrete mast cell Am J Clin Pathol ;:-

4 A B -A (,) PE-A Flow Cytometry Based / Gated Mast Cell Population Size.... FLOCK-Based Mast Cell Population Size -A (,) PE-A Figure Comparison of mast cell population size by FLOCK analysis and /side-scatter characteristic () mast cell gated events by flow cytometric analysis, showing correlation between the number of events within the broadly defined / mast cell gate by flow cytometric analysis (y-axis) and the FLOCK analysis identified mast cell population (x-axis; R =.). C -A (,) population, sensitivity was %, specificity was %, PPV was %, and NPV was % for SM. For FLOCK-identified mast cell populations with a size.% or more of the total population, sensitivity was % and specificity was % for SM. For FLOCK-identified mast cell populations with a size.% or more of the total population, sensitivity was % and specificity was % for SM. PE-A Figure Representative flow cytometry findings and FLOCK analysis findings in systemic mastocytosis (SM) and non-sm cases. A, An SM case showing a significant population of cells with event clustering within the broadly defined /side-scatter characteristic () mast cell gate by flow cytometric analysis (left panel) and with a discrete mast cell population identified by FLOCK analysis (right panel). B, An SM case showing a small population of cells with event clustering within the broadly defined / mast cell gate by flow cytometric analysis (left panel) and with a discrete mast cell population identified by FLOCK analysis (right panel). C, A non-sm case without event clustering within the broadly defined / mast cell gate by flow cytometric analysis (left panel) and without a discrete mast cell population identified by FLOCK analysis (right panel). population sizes determined by FLOCK analysis; the results are shown in Figure. The area under the ROC curve was. (% confidence interval,.-.; P <.). Based on the presence of any FLOCK-identified mast cell Comparison With Histologic Findings When FLOCK results were compared with bone marrow biopsy findings, all SM cases with apparent flow cytometry based event clusters and FLOCK-identified discrete mast cell populations more than.% of total cells and six of cases with FLOCK-identified discrete mast cell populations.% or less of total cells had mast cell aggregates present in the bone marrow biopsy comprising less than % to % of total cellularity (mean, % of total cellularity), with one exception. A case with a FLOCK-identified discrete mast cell population of.% showed increased, scattered mast cells, including spindle-shaped cells, which accounted for % of total cells, but no mast cell aggregates. The remaining SM cases contained scattered mast cells and no discrete mast cell aggregates. All SM cases with FLOCK-identified discrete mast cell populations without apparent flow cytometry based event clusters exhibited mast cell aggregates in the bone marrow biopsy comprising % to % of total cellularity, with the exception of one case with loose fibrosis and a mast cell infiltrate that comprised % of total cellularity (FLOCK-identified discrete mast cell population of.%). For SM cases without FLOCK-identified discrete mast cell Am J Clin Pathol ;:-

5 Dorfman et al / FLOCK Analysis in Systemic Mastocytosis A B C -A (,) -A (,) -A (,) PE-A PE-A PE-A populations and with available bone marrow biopsy findings, of exhibited mast cell aggregates in the bone marrow biopsy specimen, ranging in size from less than % to % of total cellularity (mean,.% of total cellularity). Figure Representative FLOCK analysis findings and flow cytometry findings in systemic mastocytosis (SM) and non-sm cases. A, An SM case showing no discernible event clustering within the broadly defined /side-scatter characteristic () mast cell gate by flow cytometric analysis (left panel) but with a mast cell population identified by FLOCK analysis (right panel). B, A non-sm case showing a small population of cells with event clustering within the broadly defined / mast cell gate by flow cytometric analysis (left panel) and with a mast cell population identified by FLOCK analysis (right panel). C, A non-sm case showing no discernible event clustering within the broadly defined / mast cell gate by flow cytometric analysis (left panel) but with a mast cell population identified by FLOCK analysis (right panel). Population Size (% of Total)... Discussion SM Samples Non-SM Samples Figure Comparison of FLOCK analysis based mast cell population sizes in systemic mastocytosis (SM) (mean population size,.%) and non-sm cases (mean population size,.%; P <.). In this study, we employed FLOCK, a computational approach that uses algorithms and density-based clustering to identify cell subsets in multidimensional flow cytometry data, to identify and quantitate mast cell populations in an unbiased, automated fashion. Previously, we found that patients who exhibited discrete mast cell event clustering by high-sensitivity flow cytometric analysis, in conjunction with aberrant CD and/or CD expression, all fulfilled WHO diagnostic criteria for SM following a complete evaluation. In fact, with the addition of event clustering as a diagnostic criterion, flow cytometric analysis was more sensitive and specific in detecting SM than bone marrow biopsy examination, the current gold standard for diagnosing SM. In our prior study, statistical analysis showed that the population of cells within a broadly defined mast cell gate had lower CVs for and in SM cases compared with non-sm cases, as well as in cases with mast cell event clustering compared with cases without mast cell event clustering. Here we sought to determine whether an automated, objective, algorithmic approach for the identification of discrete mast cell populations could be used and whether the results of such an approach would correlate with the presence of SM. In our analysis, FLOCK was able to identify discrete mast cell populations in most cases of SM (%) but only a minority of non-sm cases (%). FLOCK identified discrete mast cell populations in a number of cases in which event clustering was not detected by flow cytometric analysis alone. We also found that FLOCK-identified mast cell population size was significantly different in SM cases compared with non-sm cases (.% vs.%, P <.). A shortcoming of FLOCK analysis is the absence of assessment of the relative density of mast cell distributions within the / flow cytometric space. Preliminary Am J Clin Pathol ;:-

6 Sensitivity Specificity Increasing Mast Cell Population Size (% of Total Popuation) Any size population. Figure Receiver operating characteristic (ROC) curve analysis of FLOCK-based mast cell population size as a diagnostic criterion for systemic mastocytosis (SM). The area under the ROC curve was. (% confidence interval,.-.; P <.). For SM, the sensitivity was %, specificity was %, positive predictive value was %, and negative predictive value was % for the presence of any FLOCK-identified discrete mast cell population. As the FLOCK-identified mast cell population size increases, sensitivity for the diagnosis of SM decreases and specificity increases (eg, for mast cell populations with a size.% or more of the total population, sensitivity was % and specificity was % for SM, and for mast cell populations with a size.% or more of the total population, sensitivity was % and specificity was % for SM). analysis of the density of FLOCK-identified mast cell populations, based on a calculation of the total number of cells within the area occupied by the mast cell population (from measurements of printed two-dimensional FLOCK data), finds a mean density of, cells/cm in SM cases and cells/cm in non-sm cases (P =., Mann-Whitney; unpublished data). Consideration of the density of FLOCKidentified mast cell populations may improve the diagnostic accuracy of FLOCK analysis in the assessment of possible SM cases. FLOCK analysis was more accurate than statistical analysis of flow cytometric data at predicting the presence of SM. In our prior study, event clusters within the mast cell gate were associated with significantly lower CVs for and in SM vs non-sm cases. A combined CV ( + ) of or less showed a sensitivity of % and specificity of % for SM, with a PPV of % and an NPV of %. In the current study, the presence of FLOCKidentified discrete mast cell populations was predictive of SM, with a sensitivity of %, specificity of %, PPV of %, and NPV of %. However, based on ROC analysis of FLOCK data, relatively large-sized FLOCK-identified mast cell populations are highly specific for SM: populations with a size.% or more of the total population are % specific for SM, and populations with a size.% or more of the total population are % specific for SM. Comparison of FLOCK findings with bone marrow biopsy findings revealed that almost all SM cases with FLOCK-identified discrete mast cell populations more than.% of total cells and of cases with FLOCK-identified discrete mast cell populations.% or less of total cells had mast cell aggregates present in the bone marrow biopsy specimen. In general, there was histologic evidence of greater bone marrow involvement by SM in cases with FLOCK-identified discrete mast cell populations than in SM cases without FLOCK-identified discrete mast cell populations; however, the absence of FLOCK-identified discrete mast cell populations did not rule out bone marrow involvement by SM, which may be due in part to sampling artifact as well as marrow fibrosis, which may be seen in SM. Hence, assessment of bone marrow biopsy histologic and immunophenotypic findings remains important for the evaluation of patients with suspected SM. Previously, FLOCK was created and used to identify T-cell and B-cell subsets in patients in various immunologically challenged states, such as postvaccination, and during bacterial or viral infections. FLOCK was able to identify and quantitate specific lymphocyte subsets and to allow comparison of these subpopulations between individuals. To our knowledge, FLOCK analysis of flow cytometric data has not been employed until now to identify neoplastic cell populations in hematopoietic neoplasms. Identification of neoplastic populations usually relies on the identification of a neoplastic cell immunophenotype based on expression of specific antigens, which often recapitulate the expression of hematopoietic lineage markers at specific states of differentiation (eg, the myeloblast state or the follicular center cell state). Similarly, high-sensitivity flow cytometric analysis for minimal residual disease assessment in acute lymphoblastic leukemia is based on the detection of aberrant antigen expression or a leukemia-associated immunophenotype., In the evaluation of patients with suspected SM, a high-sensitivity flow cytometric approach has been used to identify mast cells with an aberrant CD and/or CD immunophenotype, indicative of neoplastic mast cells. - However, in our prior studies, we found that the identification of discrete mast cell event clusters by flow cytometry correlated with the presence of an aberrant mast cell phenotype and was also present in patients without an aberrant mast cell immunophenotype who otherwise fulfilled the WHO diagnostic criteria for SM., For example, in the Am J Clin Pathol ;:-

7 Dorfman et al / FLOCK Analysis in Systemic Mastocytosis current study, cases of SM demonstrated event clustering by flow cytometric analysis and discrete FLOCK-identified mast cell populations, without aberrant antigen coexpression. This finding event clustering and discrete FLOCKidentified populations within specific, flow cytometrically defined and gated populations may itself be indicative of the presence of a neoplastic population and suggests a new approach for the flow cytometric assessment of specimens from patients with suspected hematopoietic neoplasms. Preliminary FLOCK analysis of bone marrow aspiration specimens from patients with possible involvement by a plasma cell neoplasm suggests that the number and size of discrete FLOCK-identified plasma cell populations are increased in positive specimens compared with negative specimens. In conclusion, FLOCK analysis identifies discrete mast cell populations that correspond to flow cytometric mast cell event clustering in most SM cases, is predictive of SM and the presence of mast cell aggregates in the bone marrow biopsy specimen, and provides useful information for the diagnosis of patients with suspected SM, although a negative FLOCK result does not rule out bone marrow involvement. FLOCK analysis may also be useful for the objective identification of neoplastic cell populations in other hematopoietic neoplasms. Corresponding author: David M. Dorfman, MD, PhD, Dept of Pathology, Brigham and Women s Hospital, Francis St, Boston, MA ; ddorfman@partners.org. References. Swerdlow SH, Campo E, Harris NL, et al, eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. th ed. Lyon, France: IARC;.. Sanchez-Munoz L, Alvarez-Twose I, Garcia-Montero AC, et al. Evaluation of the WHO criteria for the classification of patients with mastocytosis. Mod Pathol. ;:-.. Johnson MR, Verstovsek S, Jorgensen JL, et al. Utility of the World Heath Organization classification criteria for the diagnosis of systemic mastocytosis in bone marrow. Mod Pathol. ;:-.. Pozdnyakova O, Kondtratiev S, Li B, et al. High-sensitivity flow cytometric analysis for the evaluation of systemic mastocytosis including the identification of a new flow cytometric criterion for bone marrow involvement. Am J Clin Pathol. ;:-.. Pozdnyakova O, LaPlante CD, Li B, et al. High-sensitivity flow cytometric analysis of mast cell clustering in systemic mastocytosis: a quantitative and statistical analysis. Leuk Lymphoma. ;:-.. Qian Y, Wei C, Eun-Hyung Lee F, et al. Elucidation of seventeen human peripheral blood B-cell subsets and quantification of the tetanus response using a density-based method for the automated identification of cell populations in multidimensional flow cytometry data. Cytometry B Clin Cytom. ;(suppl ):S-S.. McArthur MA, Sztein MB. Heterogeneity of multifunctional IL-A producing S. typhi specific CD+ T cells in volunteers following Tya typhoid immunization. PLoS ONE. ;:e.. Lelic A, Verschoor CP, Ventresca M, et al. The polyfunctionality of human memory CD+ T cells elicited by acute and chronic virus infections is not influenced by age. PLoS Pathog. ;:e.. McArthur MA, Sztein MB. Unexpected heterogeneity of multifunctional T cells in response to superantigen stimulation in humans. Clin Immunol. ;:-.. Henn AD, Wu S, Qiu X, et al. High-resolution temporal response patterns to influenza vaccine reveal a distinct human plasma cell gene signature. Sci Rep. ;:.. Griesinger F, Piro-Noack M, Kaib N, et al. Leukaemiaassociated immunophenotypes (LAIP) are observed in % of adult and childhood acute lymphoblastic leukaemia: detection in remission marrow predicts outcome. Br J Haematol. ;:-.. Krampera M, Perbellini O, Vincenzi C, et al. Methodological approach to minimal residual disease detection by flow cytometry in adult B-lineage acute lymphoblastic leukemia. Haematologica. ;:-.. Sanchez-Munoz L, Teodosio C, Morgado JM, et al. Immunophenotypic characterization of bone marrow mast cells in mastocytosis and other mast cell disorders. Methods Cell Biol. ;:-.. Escribano L, Diaz-Agustin B, Lopez A, et al. Immunophenotypic analysis of mast cells in mastocytosis: when and how to do it. Proposals of the Spanish Network on Mastocytosis (REMA). Cytometry B Clin Cytom. ;:-.. Escribano L, Diaz-Agustin B, Bellas C, et al. Utility of flow cytometric analysis of mast cells in the diagnosis and classification of adult mastocytosis. Leukemia Res. ;:-. Am J Clin Pathol ;:-

CME/SAM. Olga Pozdnyakova, MD, PhD, 1 Svetlana Kondtratiev, MD, 1,2 Betty Li, MS, 1 Karry Charest, 1 and David M. Dorfman, MD, PhD 1.

CME/SAM. Olga Pozdnyakova, MD, PhD, 1 Svetlana Kondtratiev, MD, 1,2 Betty Li, MS, 1 Karry Charest, 1 and David M. Dorfman, MD, PhD 1. Hematopathology / New Mastocytosis Flow Cytometry Approach High-Sensitivity Flow Cytometric Analysis for the Evaluation of Systemic Mastocytosis Including the Identification of a New Flow Cytometric Criterion

More information

ICCS e-newsletter CSI Case Laura Sánchez-Muñoz, Jose Mario T. Morgado, Cristina Teodosio

ICCS e-newsletter CSI Case Laura Sánchez-Muñoz, Jose Mario T. Morgado, Cristina Teodosio ICCS e-newsletter CSI Case Laura Sánchez-Muñoz, Jose Mario T. Morgado, Cristina Teodosio Instituto de Estudios de Mastocitosis and Centro de Investigación del Cáncer Spanish Network on Mastocytosis Spain

More information

Immunophenotyping of mast cells: a sensitive and specific diagnostic tool for systemic mastocytosis

Immunophenotyping of mast cells: a sensitive and specific diagnostic tool for systemic mastocytosis O R I G I N A L A R T I C L E Immunophenotyping of mast cells: a sensitive and specific diagnostic tool for systemic mastocytosis P.L.A. van Daele 1,2*, B.S. Beukenkamp 2, W.M.C. Geertsma-Kleinekoort 3,

More information

Mast Cell Disease Case 054 Session 7

Mast Cell Disease Case 054 Session 7 Mast Cell Disease Case 054 Session 7 Rodney R. Miles, M.D., Ph.D. Lauren B. Smith, M.D. Cem Akin, M.D. Diane Roulston,, Ph.D. Charles W. Ross, M.D. Departments of Pathology and Internal Medicine University

More information

Case Report. Introduction. Mastocytosis associated with CML Hematopathology - March K. David Li 1,*, Xinjie Xu 1, and Anna P.

Case Report. Introduction. Mastocytosis associated with CML Hematopathology - March K. David Li 1,*, Xinjie Xu 1, and Anna P. Mastocytosis associated with CML Hematopathology - March 2016 Case Report Systemic mastocytosis with associated clonal hematologic non-mast cell lineage disease (SM-AHNMD) involving chronic myelogenous

More information

Ferrata Storti Foundation

Ferrata Storti Foundation Published Ahead of Print on November 30, 2009, as doi:10.3324/haematol.2009.018911. Copyright 2009 Ferrata Storti Foundation. Early Release Paper Enhanced sensitivity of flow cytometry for routine assessment

More information

Mast Cell Disease. Daniel A. Arber, MD Stanford University, Stanford CA

Mast Cell Disease. Daniel A. Arber, MD Stanford University, Stanford CA Mast Cell Disease Daniel A. Arber, MD Stanford University, Stanford CA Mast cell disease, or mastocytosis, includes a variety of disorders that are characterized by the presence of mast cell aggregates

More information

CME/SAM. Abstract. Hematopathology / CD103 and CD123 in B-Cell Neoplasia

CME/SAM. Abstract. Hematopathology / CD103 and CD123 in B-Cell Neoplasia Hematopathology / CD103 and CD123 in B-Cell Neoplasia Characteristic CD103 and CD123 Expression Pattern Defines Hairy Cell Leukemia Usefulness of CD123 and CD103 in the Diagnosis of Mature B-Cell Lymphoproliferative

More information

Diagnostic Approach for Eosinophilia and Mastocytosis. Curtis A. Hanson, M.D.

Diagnostic Approach for Eosinophilia and Mastocytosis. Curtis A. Hanson, M.D. Diagnostic Approach for Eosinophilia and Mastocytosis Curtis A. Hanson, M.D. 2014 MFMER slide-1 DISCLOSURES: Relevant Financial Relationship(s) None Off Label Usage None 2014 MFMER slide-2 Molecular Classification

More information

2007 Workshop of Society for Hematopathology & European Association for Hematopathology Indianapolis, IN, USA Case # 228

2007 Workshop of Society for Hematopathology & European Association for Hematopathology Indianapolis, IN, USA Case # 228 2007 Workshop of Society for Hematopathology & European Association for Hematopathology Indianapolis, IN, USA Case # 228 Vishnu V. B Reddy, MD University of Alabama at Birmingham Birmingham, AL USA 11/03/07

More information

CME/SAM. Mixed Phenotype Acute Leukemia

CME/SAM. Mixed Phenotype Acute Leukemia AJCP / Original Article Mixed Phenotype Acute Leukemia A Study of 61 Cases Using World Health Organization and European Group for the Immunological Classification of Leukaemias Criteria Olga K. Weinberg,

More information

VUmc Basispresentatie

VUmc Basispresentatie Clinical diagnostic cytometry Gerrit J Schuurhuis Dept of Hematology VU University Medical Center Amsterdam, Netherlands Use of immunophenotyping at diagnosis to trace residual disease after therapy 1.

More information

Successful flow cytometric immunophenotyping of body fluid specimens

Successful flow cytometric immunophenotyping of body fluid specimens Successful flow cytometric immunophenotyping of body fluid specimens Fiona E. Craig, MD Division of Hematopathology Mayo Clinic Arizona 2017 MFMER slide-1 Financial disclosure No conflicts 2017 MFMER slide-2

More information

Significant CD5 Expression on Normal Stage 3 Hematogones and Mature B Lymphocytes in Bone Marrow

Significant CD5 Expression on Normal Stage 3 Hematogones and Mature B Lymphocytes in Bone Marrow Hematopathology / CD5 Expression on Normal B Cells Significant CD5 Expression on Normal Stage 3 Hematogones and Mature B Lymphocytes in Bone Marrow Franklin S. Fuda, DO, Nitin J. Karandikar, MD, PhD, and

More information

Case 3. Ann T. Moriarty,MD

Case 3. Ann T. Moriarty,MD Case 3 Ann T. Moriarty,MD Case 3 59 year old male with asymptomatic cervical lymphadenopathy. These images are from a fine needle biopsy of a left cervical lymph node. Image 1 Papanicolaou Stained smear,100x.

More information

Dr Prashant Tembhare

Dr Prashant Tembhare Dr Prashant Tembhare docprt@gmail.com FCM very powerful technology in Identification and characterization of neoplastic plasma cells as it allows - simultaneous assessment of multiple antigens large numbers

More information

Mimics of Lymphoma in Routine Biopsies. Mixed follicular and paracortical hyperplasia. Types of Lymphoid Hyperplasia

Mimics of Lymphoma in Routine Biopsies. Mixed follicular and paracortical hyperplasia. Types of Lymphoid Hyperplasia Mimics of Lymphoma in Routine Biopsies Patrick Treseler, MD, PhD Professor of Pathology University of California San Francisco Types of Lymphoid Hyperplasia Follicular hyperplasia (B-cells) Paracortical

More information

V. Acute leukemia. Flow cytometry in evaluation of hematopoietic neoplasms: A case-based approach

V. Acute leukemia. Flow cytometry in evaluation of hematopoietic neoplasms: A case-based approach V. Acute leukemia Evaluating a sample for an acute leukemia Acute leukemia is a neoplasm of immature myeloid or lymphoid cells characterized by a block in maturation, usually at the stage of an early progenitor

More information

Mimics of Lymphoma in Routine Biopsies. I have nothing to disclose regarding the information to be reported in this talk.

Mimics of Lymphoma in Routine Biopsies. I have nothing to disclose regarding the information to be reported in this talk. Mimics of Lymphoma in Routine Biopsies Patrick Treseler, MD, PhD Professor of Pathology University of California San Francisco I have nothing to disclose regarding the information to be reported in this

More information

Evaluation of Mast Cell Activation Syndromes: Impact of Pathology and Immunohistology

Evaluation of Mast Cell Activation Syndromes: Impact of Pathology and Immunohistology Review DOI: 10.1159/000336374 Published online: April 27, 2012 Evaluation of Mast Cell Activation Syndromes: Impact of Pathology and Immunohistology H.-P. Horny a K. Sotlar a P. Valent b a Institute of

More information

Systemic Mastocytosis: Seldomly Seen, Multiple Manifestations

Systemic Mastocytosis: Seldomly Seen, Multiple Manifestations Systemic Mastocytosis: Seldomly Seen, Multiple Manifestations Ryan Cassaday, MD HematologyFellows Conference June 3, 2011 Outline Why this topic, and case discussion Brief background Classification i of

More information

Multiparameter flow cytometry can be used to

Multiparameter flow cytometry can be used to Minimal residual disease testing in Acute Leukemia Anjum Hassan MD Assistant Professor of Pathology and Immunology, Director FISH laboratory in Anatomic Pathology, Washington University in St Louis, School

More information

ABERRANT EXPRESSION OF CD19 AND CD43

ABERRANT EXPRESSION OF CD19 AND CD43 ABERRANT EXPRESSION OF CD19 AND CD43 IN A PATIENT WITH THERAPY-RELATED ACUTE MYELOID LEUKEMIA AND A HISTORY OF MANTLE CELL LYMPHOMA Yen-Chuan Hsieh, 1 Chien-Liang Lin, 2 Chao-Jung Tsao, 2 Pin-Pen Hsieh,

More information

T. R. Golub, D. K. Slonim & Others 1999

T. R. Golub, D. K. Slonim & Others 1999 T. R. Golub, D. K. Slonim & Others 1999 Big Picture in 1999 The Need for Cancer Classification Cancer classification very important for advances in cancer treatment. Cancers of Identical grade can have

More information

FLOW CYTOMETRIC ANALYSIS OF NORMAL BONE MARROW

FLOW CYTOMETRIC ANALYSIS OF NORMAL BONE MARROW XI International Conference Hematopoiesis Immunology Budapest, June 6-7, 2014 FLO CYTOMETRIC ANALYSIS OF NORMAL BONE MARRO Bruno Brando and Arianna Gatti Hematology Laboratory and Transfusion Center Legnano

More information

Systemic mastocytosis:

Systemic mastocytosis: Systemic mastocytosis: Flow cytometry and Molecular Biology Katrien Vermeulen 21 oktober 2016 Cuteanous mastocytosis Major criterion Typical skin lesions of mastocytosis associated with Darier s sign Minor

More information

Evaluation of the WHO criteria for the classification of patients with mastocytosis

Evaluation of the WHO criteria for the classification of patients with mastocytosis 2011 USCAP, Inc. All rights reserved 0893-3952/11 $32.00 1 Evaluation of the WHO criteria for the classification of patients with Laura Sánchez-Muñoz 1, Ivan Alvarez-Twose 1, Andrés C García-Montero 2,

More information

The spectrum of flow cytometry of the bone marrow

The spectrum of flow cytometry of the bone marrow The spectrum of flow cytometry of the bone marrow Anna Porwit Lund University Faculty of Medicine Dept. of Clinical Sciences Div. Oncology and Pathology anna.porwit@med.lu.se Disclosure of speaker s interests

More information

Standard immunophenotyping of leukemia cells in acute myeloid leukemia (AML)

Standard immunophenotyping of leukemia cells in acute myeloid leukemia (AML) Clinical immunology Standard immunophenotyping of leukemia cells in acute myeloid leukemia (AML) ` JOLANTA WOZNIAK, JOANNA KOPEÆ-SZLÊZAK Department of Haematological Cytobiology, Institut of Haematology

More information

ADx Bone Marrow Report. Patient Information Referring Physician Specimen Information

ADx Bone Marrow Report. Patient Information Referring Physician Specimen Information ADx Bone Marrow Report Patient Information Referring Physician Specimen Information Patient Name: Specimen: Bone Marrow Site: Left iliac Physician: Accession #: ID#: Reported: 08/19/2014 - CHRONIC MYELOGENOUS

More information

De novo mast cell leukemia without CD25 expression and KIT mutations: a rare case report in a 13-year-old child

De novo mast cell leukemia without CD25 expression and KIT mutations: a rare case report in a 13-year-old child Zheng et al. Diagnostic Pathology (2018) 13:14 https://doi.org/10.1186/s13000-018-0691-2 CASE REPORT Open Access De novo mast cell leukemia without CD25 expression and KIT mutations: a rare case report

More information

9/25/2017. Disclosure. I have nothing to disclose. Young S. Kim MD Dept. of Pathology

9/25/2017. Disclosure. I have nothing to disclose. Young S. Kim MD Dept. of Pathology Disclosure MAST CELLNEOPLASM I have nothing to disclose. Young S. Kim MD Dept. of Pathology 1 Objectives What is mast cell lineage? Changes in updated WHO 2016 mastocytosis Issues of Mastocytosis CD30

More information

CME/SAM. Flow Cytometric Immunophenotyping of Cerebrospinal Fluid Specimens

CME/SAM. Flow Cytometric Immunophenotyping of Cerebrospinal Fluid Specimens Hematopathology / Flow Cytometric Immunophenotyping of CSF Specimens Flow Cytometric Immunophenotyping of Cerebrospinal Fluid Specimens Fiona E. Craig, MD, 1 N. Paul Ohori, MD, 2 Timothy S. Gorrill, MD,

More information

Clinical question. Screening tube. Diagnostic panel MRD. Clinical question

Clinical question. Screening tube. Diagnostic panel MRD. Clinical question OW CYTOMETRY UPDATES IN LYMPHOPROLIFERATIVE DISORDERS CANCER RESEARCH CENTER IBSAL UNIVERSITY & UNIVERSITY HOSPITAL, SALAMANCA (SPAIN) DISCLOSURES The EuroFlow Scientific Consortium Iamco-chairof receives

More information

NUP214-ABL1 Fusion: A Novel Discovery in Acute Myelomonocytic Leukemia

NUP214-ABL1 Fusion: A Novel Discovery in Acute Myelomonocytic Leukemia Case 0094 NUP214-ABL1 Fusion: A Novel Discovery in Acute Myelomonocytic Leukemia Jessica Snider, MD Medical University of South Carolina Case Report - 64 year old Caucasian Male Past Medical History Osteoarthritis

More information

Evaluation of a Single-Platform Technology for Lymphocyte Immunophenotyping

Evaluation of a Single-Platform Technology for Lymphocyte Immunophenotyping CLINICAL AND VACCINE IMMUNOLOGY, Oct. 2007, p. 1342 1348 Vol. 14, No. 10 1556-6811/07/$08.00 0 doi:10.1128/cvi.00168-07 Copyright 2007, American Society for Microbiology. All Rights Reserved. Evaluation

More information

Fortgeschrittene systemische Mastozytose Hintergrundinformationen zu einer seltenen Erkrankung und zur ersten zugelassenen Therapie

Fortgeschrittene systemische Mastozytose Hintergrundinformationen zu einer seltenen Erkrankung und zur ersten zugelassenen Therapie Fortgeschrittene systemische Mastozytose Hintergrundinformationen zu einer seltenen Erkrankung und zur ersten zugelassenen Therapie Georgia Metzgeroth Hämatologie und Onkologie III. Medizinische Klinik

More information

Diagnostic Usefulness of CD23 and FMC-7 Antigen Expression Patterns in B-Cell Lymphoma Classification

Diagnostic Usefulness of CD23 and FMC-7 Antigen Expression Patterns in B-Cell Lymphoma Classification Hematopathology / AND ANTIGEN EXPRESSION IN B-CELL LYMPHOMA CLASSIFICATION Diagnostic Usefulness of and Antigen Expression Patterns in B-Cell Lymphoma Classification Diana P. Garcia, MD, 1* Michele T.

More information

Exploring S. Typhi-Specific HLA-E Restricted Immune Responses in Pediatric and Adult Ty21a Recipients

Exploring S. Typhi-Specific HLA-E Restricted Immune Responses in Pediatric and Adult Ty21a Recipients Exploring S. Typhi-Specific HLA-E Restricted Immune Responses in Pediatric and Adult Ty21a Recipients Mark Rudolph PhD Candidate- University of Maryland Graduate Program in Life Sciences Institute for

More information

Independent Diagnostic Accuracy of Flow Cytometry Obtained From Fine-Needle Aspirates A 10-Year Experience With 451 Cases

Independent Diagnostic Accuracy of Flow Cytometry Obtained From Fine-Needle Aspirates A 10-Year Experience With 451 Cases Hematopathology / Diagnostic Accuracy of Flow Cytometry Independent Diagnostic Accuracy of Flow Cytometry Obtained From Fine-Needle Aspirates A 10-Year Experience With 451 Cases Erica C. Savage, MD, 1

More information

Test Utilization: Chronic Lymphocytic Leukemia

Test Utilization: Chronic Lymphocytic Leukemia Test Utilization: Chronic Lymphocytic Leukemia Initial Evaluation Diagnostic Criteria Selection of Tests for Prognosis Response to Therapy Challenges Assessment for persistent disease Paul J. Kurtin, M.D.

More information

Flow Cytometric Analysis of CD5+ B Cells A Frame of Reference for Minimal Residual Disease Analysis in Chronic Lymphocytic Leukemia

Flow Cytometric Analysis of CD5+ B Cells A Frame of Reference for Minimal Residual Disease Analysis in Chronic Lymphocytic Leukemia Hematopathology / CD5+ -CELL NLYSIS Y FLOW CYTOMETRY Flow Cytometric nalysis of CD5+ Cells Frame of Reference for Minimal Residual Disease nalysis in Chronic Lymphocytic Leukemia Ritu Gupta, MD, 1 Paresh

More information

HEMATOPATHOLOGY (SHANDS HOSPITAL AT THE UNIVERSITY OF FLORIDA): Rotation Director: Ying Li, M.D., Ph.D., Assistant Professor

HEMATOPATHOLOGY (SHANDS HOSPITAL AT THE UNIVERSITY OF FLORIDA): Rotation Director: Ying Li, M.D., Ph.D., Assistant Professor HEMATOPATHOLOGY (SHANDS HOSPITAL AT THE UNIVERSITY OF FLORIDA): Rotation Director: Ying Li, M.D., Ph.D., Assistant Professor I. Description of the rotation: During this rotation, the resident will gain

More information

Differential diagnosis of hematolymphoid tumors composed of medium-sized cells. Brian Skinnider B.C. Cancer Agency, Vancouver General Hospital

Differential diagnosis of hematolymphoid tumors composed of medium-sized cells. Brian Skinnider B.C. Cancer Agency, Vancouver General Hospital Differential diagnosis of hematolymphoid tumors composed of medium-sized cells Brian Skinnider B.C. Cancer Agency, Vancouver General Hospital Lymphoma classification Lymphoma diagnosis starts with morphologic

More information

Diagnostic challenge: Acute leukemia with biphenotypic blasts and BCR-ABL1 translocation

Diagnostic challenge: Acute leukemia with biphenotypic blasts and BCR-ABL1 translocation Case Study Diagnostic challenge: Acute leukemia with biphenotypic blasts and BCR-ABL1 translocation Ling Wang 1 and Xiangdong Xu 1,2,* 1 Department of Pathology, University of California, San Diego; 2

More information

Acute myeloid leukaemia with t(8;21) associated with occult mastocytosis. Report of an unusual case and review of the literature

Acute myeloid leukaemia with t(8;21) associated with occult mastocytosis. Report of an unusual case and review of the literature 324 CASE REPORT Acute myeloid leukaemia with t(8;21) associated with occult mastocytosis. Report of an unusual case and review of the literature H-W Bernd, K Sotlar, J Lorenzen, R Osieka, U Fabry, P Valent,

More information

Do Your Flow Cytometric LDTs. Validation Guidelines? Fiona E. Craig, MD University of Pittsburgh School of Medicine

Do Your Flow Cytometric LDTs. Validation Guidelines? Fiona E. Craig, MD University of Pittsburgh School of Medicine Do Your Flow Cytometric LDTs Conform to the ICSH ICCS Validation Guidelines? Fiona E. Craig, MD University of Pittsburgh School of Medicine How should LDTs be validated? Accuracy Specificity Sensitivity

More information

BCR-ABL1 positive Myeloid Sarcoma Nicola Austin

BCR-ABL1 positive Myeloid Sarcoma Nicola Austin BCR-ABL1 positive Myeloid Sarcoma Nicola Austin Cytocell UK & Ireland User Group Meeting Jesus College, Cambridge 4 th - 5 th April 2017 Myeloid Sarcoma WHO Classification Tumours of Haematopoietic and

More information

Reactive and Neoplastic Lymphocytosis

Reactive and Neoplastic Lymphocytosis Reactive and Neoplastic Lymphocytosis Koranda A. Walsh, VMD, BS Assistant Professor, Clinical Pathobiology University of Pennsylvania School of Veterinary Medicine PLEASE NOTE: These notes are meant as

More information

59 Manifestações cutâneas em indivíduos infectados ou com doenças 59

59 Manifestações cutâneas em indivíduos infectados ou com doenças 59 59 Manifestações cutâneas em indivíduos infectados ou com doenças 59 INVESTIGATION s Adult mastocytosis: a review of the Santo António Hospital 's experience and an evaluation of World Health Organization

More information

PhenoPath. Diagnoses you can count on B CELL NON-HODGKIN LYMPHOMA

PhenoPath. Diagnoses you can count on B CELL NON-HODGKIN LYMPHOMA PhenoPath Diagnoses you can count on B CELL NON-HODGKIN LYMPHOMA C urrent diagnosis of B cell non-hodgkin lymphoma (B-NHL) is based on the 2008 WHO Classification of Tumours of Haematopoietic and Lymphoid

More information

Flow cytometric analysis of B-cell lymphoproliferative disorders

Flow cytometric analysis of B-cell lymphoproliferative disorders Flow cytometric analysis of B-cell lymphoproliferative disorders David M. Dorfman, M.D., Ph.D. Department of Pathology Brigham and Women s Hospital and Harvard Medical School Boston, MA Objectives Review

More information

Flow Cytometric Analysis of Surface Light Chain Expression Patterns in B-Cell Lymphomas Using Monoclonal and Polyclonal Antibodies

Flow Cytometric Analysis of Surface Light Chain Expression Patterns in B-Cell Lymphomas Using Monoclonal and Polyclonal Antibodies Hematopathology / Light Chain Expression in B-NHLs Flow Cytometric Analysis of Surface Light Chain Expression Patterns in B-Cell Lymphomas Using Monoclonal and Polyclonal Antibodies Pedro Horna, MD, Horatiu

More information

How I Handle Mast Cells in GI Biopsies

How I Handle Mast Cells in GI Biopsies How I Handle Mast Cells in GI Biopsies Dora Lam-Himlin, MD Rodger C. Haggitt Gastrointestinal Pathology Society Forum United States and Canadian Academy of Pathologists Seattle, Washington, March 12, 2016

More information

Comparison of myeloperoxidase detection by flow cytometry using two different clones of monoclonal antibodies

Comparison of myeloperoxidase detection by flow cytometry using two different clones of monoclonal antibodies Malaysian J Pathol 2004; 26(2) : 111 116FLOW CYTOMETRY MYELOPEROXIDASE DETECTION Comparison of myeloperoxidase detection by flow cytometry using two different clones of monoclonal antibodies CF Leong MPath,

More information

JMSCR Vol. 03 Issue 06 Page June 2015

JMSCR Vol. 03 Issue 06 Page June 2015 www.jmscr.igmpublication.org Impact Factor 3.79 ISSN (e)-2347-176x An Indolent Natural Killer Cell Leukemia Presenting with Bilateral Ankle Arthritis and Low Grade Fever Abstract Author Subhash Chandra

More information

Supplementary Materials Extracting a Cellular Hierarchy from High-dimensional Cytometry Data with SPADE

Supplementary Materials Extracting a Cellular Hierarchy from High-dimensional Cytometry Data with SPADE Supplementary Materials Extracting a Cellular Hierarchy from High-dimensional Cytometry Data with SPADE Peng Qiu1,4, Erin F. Simonds2, Sean C. Bendall2, Kenneth D. Gibbs Jr.2, Robert V. Bruggner2, Michael

More information

Hemophagocytic Lymphohistiocytosis Secondary to T cell/histiocyte-rich Large B-cell Lymphoma

Hemophagocytic Lymphohistiocytosis Secondary to T cell/histiocyte-rich Large B-cell Lymphoma Hemophagocytic Lymphohistiocytosis Secondary to T cell/histiocyte-rich Large B-cell Lymphoma Katherine Devitt, M.D., Benjamin Chen, M.D., Ph.D., Hongbo Yu, M.D., Ph.D., Bruce Woda, M.D. 1 1 Department

More information

Getting Beyond the Flags: Quantitative assessment of immature granulocyte (IG) populations may improve the assessment of sepsis and inflammation.

Getting Beyond the Flags: Quantitative assessment of immature granulocyte (IG) populations may improve the assessment of sepsis and inflammation. Getting Beyond the Flags: Quantitative assessment of immature granulocyte (IG) populations may improve the assessment of sepsis and inflammation. Sysmex America White Paper One Nelson C. White Parkway,

More information

x Lymphocyte count /µl CD8+ count/µl 800 Calculated

x Lymphocyte count /µl CD8+ count/µl 800 Calculated % Lymphocyte in CBC A. 50 40 30 20 10 Lymphocyte count /µl B. x10 3 2.5 1.5 C. 50 D. 1000 % CD3+CD8+ Cells 40 30 20 Calculated CD8+ count/µl 800 600 400 200 10 0 #61 #63 #64 #65 #68 #71 #72 #75 Figure

More information

Eosinophilia: A Diagnostic Approach and Test Utilization Strategies for Bone Marrow Evaluation

Eosinophilia: A Diagnostic Approach and Test Utilization Strategies for Bone Marrow Evaluation Eosinophilia: A Diagnostic Approach and Test Utilization Strategies for Bone Marrow Evaluation American Society for Clinical Pathology 2014 Annual Meeting Presented by: Matthew T. Howard, MD Assistant

More information

Normal Blood and Bone Marrow Populations

Normal Blood and Bone Marrow Populations 4 CHAPTER 4 Normal Blood and Bone Marrow Populations It is essential to have a sound understanding of the nature and immunophenotypic characteristics of the normal cell populations encountered in bone

More information

Critical Analysis and Diagnostic Usefulness of Limited Immunophenotyping of B-Cell Non-Hodgkin Lymphomas by Flow Cytometry

Critical Analysis and Diagnostic Usefulness of Limited Immunophenotyping of B-Cell Non-Hodgkin Lymphomas by Flow Cytometry Hematopathology / FLOW CYTOMETRIC IMMUNOPHENOTYPING IN B-CELL NON-HODGKIN LYMPHOMA Critical Analysis and Diagnostic Usefulness of Limited Immunophenotyping of B-Cell Non-Hodgkin Lymphomas by Flow Cytometry

More information

CHAPTER 3 LABORATORY PROCEDURES

CHAPTER 3 LABORATORY PROCEDURES CHAPTER 3 LABORATORY PROCEDURES CHAPTER 3 LABORATORY PROCEDURES 3.1 HLA TYPING Molecular HLA typing will be performed for all donor cord blood units and patients in the three reference laboratories identified

More information

Aggressive B-cell Lymphomas Updated WHO classification Elias Campo

Aggressive B-cell Lymphomas Updated WHO classification Elias Campo Aggressive B-cell Lymphomas Updated WHO classification Elias Campo Hospital Clinic, University of Barcelona Diffuse Large B-cell Lymphoma A Heterogeneous Category Subtypes with differing: Histology and

More information

Peripheral blood Pleural effusion in a cat

Peripheral blood Pleural effusion in a cat Tools for the Diagnosis of Lymphoproliferative Diseases When is it difficult to diagnose lymphoproliferative disease? Persistent lymphocytosis consisting of small Lymph node aspirates containing an excess

More information

Evaluation of a Method for Counting Absolute Numbers of Cells with a Flow Cytometer

Evaluation of a Method for Counting Absolute Numbers of Cells with a Flow Cytometer CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY, May 1997, p. 309 313 Vol. 4, No. 3 1071-412X/97/$04.00 0 Copyright 1997, American Society for Microbiology Evaluation of a Method for Counting Absolute Numbers

More information

Flow Cytometric Analysis of Cerebral Spinal Fluid Involvement by Leukemia or Lymphoma

Flow Cytometric Analysis of Cerebral Spinal Fluid Involvement by Leukemia or Lymphoma Flow Cytometric Analysis of Cerebral Spinal Fluid Involvement by Leukemia or Lymphoma Maryalice Stetler-Stevenson, M.D., Ph.D. Flow Cytometry Unit, Laboratory of Pathology, DCS, NCI, NIH DEPARTMENT OF

More information

Case Report Parotid gland follicular lymphoma lacking both cytoplasmic and surface light chains: a rare case

Case Report Parotid gland follicular lymphoma lacking both cytoplasmic and surface light chains: a rare case Int J Clin Exp Pathol 2014;7(10):7100-7104 www.ijcep.com /ISSN:1936-2625/IJCEP0001717 Case Report Parotid gland follicular lymphoma lacking both cytoplasmic and surface light chains: a rare case Jenny

More information

Immunopathology of Lymphoma

Immunopathology of Lymphoma Immunopathology of Lymphoma Noraidah Masir MBBCh, M.Med (Pathology), D.Phil. Department of Pathology Faculty of Medicine Universiti Kebangsaan Malaysia Lymphoma classification has been challenging to pathologists.

More information

Lack of Surface Immunoglobulin Light Chain Expression by Flow Cytometric Immunophenotyping Can Help Diagnose Peripheral B-Cell Lymphoma

Lack of Surface Immunoglobulin Light Chain Expression by Flow Cytometric Immunophenotyping Can Help Diagnose Peripheral B-Cell Lymphoma Hematopathology / SURFACE IMMUNOGLOBULIN LIGHT CHAIN NEGATIVE PERIPHERAL B-CELL LYMPHOMA Lack of Surface Immunoglobulin Light Chain Expression by Flow Cytometric Immunophenotyping Can Help Diagnose Peripheral

More information

CLINICAL USE OF CELLULAR SUBPOPULATION ANALYSIS IN BM

CLINICAL USE OF CELLULAR SUBPOPULATION ANALYSIS IN BM CLINICAL USE OF CELLULAR SUBPOPULATION ANALYSIS IN BM CANCER RESEARCH CENTRE, UNIVERSITY AND UNIVERSITY HOSPITAL OF SALAMANCA (SPAIN)( Sao Paulo, 18th of April, 2009 IDENTIFICATION OF HPC (I) 1.- In vivo

More information

Template for Reporting Results of Biomarker Testing for Myeloproliferative Neoplasms

Template for Reporting Results of Biomarker Testing for Myeloproliferative Neoplasms Template for Reporting Results of Biomarker Testing for Myeloproliferative Neoplasms Version: MPNBiomarkers 1.0.0.2 Protocol Posting Date: June 2017 This biomarker template is NOT required for accreditation

More information

FLOW CYTOMETRY PRINCIPLES AND PRACTICE. Toby Eyre Consultant Haematologist Oxford University Hospitals NHS Foundation Trust June 2018

FLOW CYTOMETRY PRINCIPLES AND PRACTICE. Toby Eyre Consultant Haematologist Oxford University Hospitals NHS Foundation Trust June 2018 FLOW CYTOMETRY PRINCIPLES AND PRACTICE Toby Eyre Consultant Haematologist Oxford University Hospitals NHS Foundation Trust June 2018 Aims and Objectives Principles of flow cytometry Preparation Steps involved

More information

Molecular Advances in Hematopathology

Molecular Advances in Hematopathology Molecular Advances in Hematopathology HOW MOLECULAR METHODS HAVE CHANGED MY PRACTICE Objectives Understand the importance of cytogenetic/molecular studies in hematolymphoid diseases Know some of the important

More information

T he World Health Organisation (WHO) classification of

T he World Health Organisation (WHO) classification of 604 ORIGINAL ARTICLE Systemic mastocytosis with associated clonal haematological non-mast cell lineage diseases: a histopathological challenge H-P Horny, K Sotlar, W R Sperr, P Valent... See end of article

More information

Aberrant Expression of CD7 in Myeloblasts Is Highly Associated With De Novo Acute Myeloid Leukemias With FLT3/ITD Mutation

Aberrant Expression of CD7 in Myeloblasts Is Highly Associated With De Novo Acute Myeloid Leukemias With FLT3/ITD Mutation Hematopathology / CD7 Expression and FLT3/ITD Mutation in AML Aberrant Expression of CD7 in Myeloblasts Is Highly Associated With De Novo Acute Myeloid Leukemias With FLT3/ITD Mutation Veronica Rausei-Mills,

More information

Levels of expression of CD19 and CD20 in chronic B cell leukaemias

Levels of expression of CD19 and CD20 in chronic B cell leukaemias 364 Academic Department of Haematology and Cytogenetics, The Royal Marsden Hospital and Institute of Cancer Research, London SW3, UK E Matutes N Farahat R Morilla D Catovsky Department of Internal Medicine,

More information

Trispecific killer engager CD16xIL15xCD33 potently induces NK cell activation and cytotoxicity against neoplastic mast cells

Trispecific killer engager CD16xIL15xCD33 potently induces NK cell activation and cytotoxicity against neoplastic mast cells STIMULUS REPORT Trispecific killer engager CD16xILxCD33 potently induces NK cell activation and cytotoxicity against neoplastic mast cells Hyun Don Yun, 1 Martin Felices, 1 Daniel A. Vallera, 2 Peter Hinderlie,

More information

June 11, Ella Noel, D.O., FACOI 1717 West Broadway Madison, WI

June 11, Ella Noel, D.O., FACOI 1717 West Broadway Madison, WI June 11, 2018 Ella Noel, D.O., FACOI 1717 West Broadway Madison, WI 53713 policycomments@wpsic.com RE: Draft Local Coverage Determination: MolDX: MDS FISH (DL37772) Dear Dr. Noel Thank you for the opportunity

More information

Changes to the Hematopoietic and Lymphoid Neoplasm Coding Manual

Changes to the Hematopoietic and Lymphoid Neoplasm Coding Manual Changes to the Hematopoietic and Lymphoid Neoplasm Coding Manual KCR 2018 SPRING TRAINING 2018 Hematopoietic Database Updates Updates were done to the Hematopoietic Database based on the WHO Hematopoietic

More information

Establishing a Pure Lymphocyte Gate for Subset Analysis by Flow Cytometry

Establishing a Pure Lymphocyte Gate for Subset Analysis by Flow Cytometry Cytornetry (Communications in Clinical Cytometry) 26:172-177 (1996) Establishing a Pure Lymphocyte Gate for Subset nalysis by Flow Cytometry Joseph M. Homtinovich, Sara D. Sparks, and Karen P. Mann Clinical

More information

How I Handle Mast Cells in GI Biopsies

How I Handle Mast Cells in GI Biopsies How I Handle Mast Cells in GI Biopsies Dora Lam-Himlin, MD Mayo Clinic Scottsdale, AZ Rodger C. Haggitt Gastrointestinal Pathology Society Forum United States and Canadian Academy of Pathologists Seattle,

More information

Anaplastic Large Cell Lymphoma A Flow Cytometric Analysis of 29 Cases

Anaplastic Large Cell Lymphoma A Flow Cytometric Analysis of 29 Cases Hematopathology / FLOW CYTOMETRY OF ANAPLASTIC LYMPHOMA Anaplastic Large Cell Lymphoma A Flow Cytometric Analysis of 29 Cases Melissa V. Kesler, MD, Geeta S. Paranjape, MD, Sheryl L. Asplund, MD, Robert

More information

Integrated Hematopathology. Morphology and FCI with IHC

Integrated Hematopathology. Morphology and FCI with IHC Integrated Hematopathology Morphology and FCI with IHC FrontMatter.indd i 9/6/2009 9:30:12 PM FrontMatter.indd ii 9/6/2009 9:30:18 PM Integrated Hematopathology Morphology and FCI with IHC Cherie H Dunphy,

More information

MYELODYSPLASTIC SYNDROMES: A diagnosis often missed

MYELODYSPLASTIC SYNDROMES: A diagnosis often missed MYELODYSPLASTIC SYNDROMES: A diagnosis often missed D R. EMMA W YPKEMA C O N S U LTA N T H A E M AT O L O G I S T L A N C E T L A B O R AT O R I E S THE MYELODYSPLASTIC SYNDROMES DEFINITION The Myelodysplastic

More information

Original Article Acute Leukemias And Aberrant Markers Expression Pak Armed Forces Med J 2018; 68 (3):

Original Article Acute Leukemias And Aberrant Markers Expression Pak Armed Forces Med J 2018; 68 (3): Open Access Original Article Acute Leukemias And Aberrant Markers Expression Pak Armed Forces Med J 2018; 68 (3): 450-54 SPECTRUM OF ACUTE LEUKEMIAS AND ABERRANT MARKERS EXPRESSION BASED ON FLOWCYTOMETRY

More information

Case Workshop of Society for Hematopathology and European Association for Haematopathology

Case Workshop of Society for Hematopathology and European Association for Haematopathology Case 148 2007 Workshop of Society for Hematopathology and European Association for Haematopathology Robert P Hasserjian Department of Pathology Massachusetts General Hospital Boston, MA Clinical history

More information

Transient Myeloproliferative Disorder and Acute Myeloid Leukemia in Down Syndrome An Immunophenotypic Analysis

Transient Myeloproliferative Disorder and Acute Myeloid Leukemia in Down Syndrome An Immunophenotypic Analysis Hematopathology / IMMUNOPHENOTYPE OF TRNSIENT MYELOPROLIFERTIVE DISORDER VS ML IN DOWN SYNDROME Transient Myeloproliferative Disorder and cute Myeloid Leukemia in Down Syndrome n Immunophenotypic nalysis

More information

ACCME/Disclosures 4/13/2016. Clinical History

ACCME/Disclosures 4/13/2016. Clinical History ACCME/Disclosures The USCAP requires that anyone in a position to influence or control the content of CME disclose any relevant financial relationship WITH COMMERCIAL INTERESTS which they or their spouse/partner

More information

CME. The Role of Multiparameter Flow Cytometry for Detection of Minimal Residual Disease in Acute Myeloid Leukemia

CME. The Role of Multiparameter Flow Cytometry for Detection of Minimal Residual Disease in Acute Myeloid Leukemia Hematopathology / Minimal Residual Disease in AML The Role of Multiparameter Flow Cytometry for Detection of Minimal Residual Disease in Acute Myeloid Leukemia Adhra Al-Mawali, PhD, 1-3 David Gillis, MBBS,

More information

Myelodysplasia/Myeloproliferative Neoplasms (MDS/MPN) Post-HCT Data

Myelodysplasia/Myeloproliferative Neoplasms (MDS/MPN) Post-HCT Data Instructions for Myelodysplasia/Myeloproliferative Neoplasms (MDS/MPN) Post-HCT Data (Form 2114) This section of the CIBMTR Forms Instruction Manual is intended to be a resource for completing the Myelodysplasia/Myeloproliferative

More information

Retrospective data analysis of all requests for flow cytometric immunophenotyping in a tertiary hospital setting

Retrospective data analysis of all requests for flow cytometric immunophenotyping in a tertiary hospital setting Peer reviewed ORIGINAL ARTICLE Retrospective data analysis of all requests for flow cytometric immunophenotyping in a tertiary hospital setting A Prinsloo MSc J Nel MMed (Haem) R Pool MMed (Haem) Tshwane

More information

Lymphoid Neoplasms Associated With IgM Paraprotein A Study of 382 Patients

Lymphoid Neoplasms Associated With IgM Paraprotein A Study of 382 Patients Hematopathology / LYMPHOMAS WITH IGM PARAPROTEIN Lymphoid Neoplasms Associated With IgM Paraprotein A Study of 382 Patients Pei Lin, MD, 1 Suyang Hao, MD, 1* Beverly C. Handy, MD, 2 Carlos E. Bueso-Ramos,

More information

Mastocytosis An Unusual Clonal Disorder of Bone Marrow Derived Hematopoietic Progenitor Cells

Mastocytosis An Unusual Clonal Disorder of Bone Marrow Derived Hematopoietic Progenitor Cells Mastocytosis An Unusual Clonal Disorder of Bone Marrow Derived Hematopoietic Progenitor Cells Hans-Peter Horny, MD Key Words: Mastocytosis; Mast cell; Bone marrow; KITD816V; Systemic mastocytosis with

More information

DETERMINATION OF A LYMPHOID PROCESS

DETERMINATION OF A LYMPHOID PROCESS Chapter 2 Applications of Touch Preparation Cytology to Intraoperative Consultations: Lymph Nodes and Extranodal Tissues for Evaluation of Hematolymphoid Disorders INTRODUCTION As discussed in Chap. 1,

More information

Classification of Hematologic Malignancies. Patricia Aoun MD MPH

Classification of Hematologic Malignancies. Patricia Aoun MD MPH Classification of Hematologic Malignancies Patricia Aoun MD MPH Objectives Know the basic principles of the current classification system for hematopoietic and lymphoid malignancies Understand the differences

More information